CRSP · CRISPR Therapeutics AG
United States · RS rating 41 · As of 2026-11-03
| Price | 49.99 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 41 / 30 / 56 / 35 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 31 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -17.1% |
| Sales growth Q/Q | +900.0% |
| Distance from 52-week high | +19.3% |
| Market cap (USD) | $5.3B |